Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma. Future oncology (London, England) Paul, B., Liedtke, M., Khouri, J., Rifkin, R., Gandhi, M. D., Kin, A., Levy, M. Y., Silbermann, R., Cottini, F., Sborov, D. W., Sandhu, I., Villarreal, L., Murphy, M., Gu, L., Chen, A., Rajakumaraswamy, N., Usmani, S. Z. 2023

Abstract

Magrolimab is a monoclonal antibody that blocks CD47, a 'do not eat me' signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).

View details for DOI 10.2217/fon-2022-0975

View details for PubMedID 36779512